Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 83.8%

Gross margin was 83.8% in Q1 FY2026, down 3.5 pp from a year earlier. On a trailing-twelve-month basis it was 82.3%, down 3.8 pp year over year. Over 3 fiscal years it widened by 1.2 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
83.8%+0.9 pp QoQ
Last fiscal yearDec 2025
85.2%-0.8 pp YoY
LTMMar 2026
82.3%-3.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.5 pp——
1 year-0.8 pp——
3 years+1.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
85.2%
Year-over-year change
-0.8pp

Gross Margin vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 gross margin of 82.3% is the 2nd highest of the 8 companies compared; the peer median is 54.5%.
  • Its year-over-year change of -3.8 pp is the 6th highest of 7, against a peer median of +1.8 pp.
  • Over three fiscal years its change of +1.2 pp compares with a peer median of -3.7 pp.
CPRX Competitors Peer median
Gross Margin for CPRX and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202682.3% -3.8 pp+1.2 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202682.1% +2.3 pp-9.4 pp
ADPTAdaptive Biotechnologies CorporationLTM Jun 202675.4% +9.4 pp+5.5 pp
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 202654.5% +1.4 pp-35.0 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-8.7% +943.2 pp+2.0 pp
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026-46.7% -42.9 pp-40.3 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-8236.0% ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding CPRX) 54.5%+1.8 pp-3.7 pp

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.83M214.2M398.2M491.73M588.99M
Cost of Revenue21.88M34.39M51.97M68.85M87.25M
Gross Profit118.95M179.81M346.24M422.89M501.74M
Gross Margin84.5%83.9%86.9%86.0%85.2%
Research & Development16.94M19.79M93.15M12.65M12.71M
Selling, General & Admin49.63M57.09M133.71M177.74M193.75M
Operating Expenses66.56M77.97M259.43M227.77M243.96M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
EBITDA52.86M105.96M127.39M254.04M321.39M
EBITDA Margin37.5%49.5%32.0%51.7%54.6%
Operating Income52.39M101.84M86.81M195.12M257.78M
Operating Margin37.2%47.5%21.8%39.7%43.8%
Interest Income00016.06M0
Interest Expense00000
Other Income / Expenses282K2.88M7.7M21.14M25.74M
Income Before Tax52.67M104.72M94.51M216.26M283.52M
Pre-Tax Margin37.4%48.9%23.7%44.0%48.1%
Income Tax Expense13.19M21.64M23.1M52.37M69.19M
Net Income39.48M83.08M71.41M163.89M214.33M
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (Basic)0.380.800.671.381.75
EPS (Diluted)0.370.750.631.311.68
Weighted Avg Shares103.38M103.37M106.28M118.46M122.29M
Weighted Avg Shares (Diluted)107.8M111.38M113.75M124.94M127.26M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.